• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.

作者信息

Yuasa Takeshi

机构信息

Department of Medical Oncology and Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo, Japan

出版信息

Int J Urol. 2009 Sep;16(9):731-2. doi: 10.1111/j.1442-2042.2009.02367.x.

DOI:10.1111/j.1442-2042.2009.02367.x
PMID:19769657
Abstract
摘要

相似文献

1
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.多西他赛联合唑来膦酸及泼尼松用于激素难治性前列腺癌的化疗：预测疗效及生存的因素的编者按
Int J Urol. 2009 Sep;16(9):731-2. doi: 10.1111/j.1442-2042.2009.02367.x.
2
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.多西他赛联合唑来膦酸及泼尼松用于激素难治性前列腺癌的化疗：预测疗效及生存的因素
Int J Urol. 2009 Sep;16(9):726-31. doi: 10.1111/j.1442-2042.2009.02351.x.
3
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.多西他赛与唑来膦酸联合治疗对前列腺癌细胞的体外相加/协同抗肿瘤作用。
Acta Oncol. 2005;44(6):644-50. doi: 10.1080/02841860510029617.
4
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.激素难治性前列腺癌患者中，多西他赛每周给药一次，唑来膦酸每4周给药一次。
Cancer Chemother Pharmacol. 2006 Jan;57(1):46-51. doi: 10.1007/s00280-005-0025-4. Epub 2005 Nov 5.
5
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.多中心随机II期研究：多西他赛、雌莫司汀和泼尼松两种给药方案对比米托蒽醌加泼尼松用于转移性激素难治性前列腺癌患者的疗效
J Clin Oncol. 2005 May 20;23(15):3343-51. doi: 10.1200/JCO.2005.12.187. Epub 2005 Feb 28.
6
Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.多西他赛、雌莫司汀和泼尼松治疗激素难治性前列腺癌：单中心经验
Anticancer Res. 2005 Nov-Dec;25(6C):4481-6.
7
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.多西他赛、磷酸雌莫司汀和唑来膦酸联合治疗雄激素非依赖性转移性前列腺癌：疗效、安全性及临床获益评估
Urology. 2005 Jan;65(1):126-30. doi: 10.1016/j.urology.2004.08.041.
8
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.批准摘要：多西他赛联合泼尼松用于治疗雄激素非依赖性激素难治性前列腺癌。
Clin Cancer Res. 2004 Dec 15;10(24):8147-51. doi: 10.1158/1078-0432.CCR-04-1402.
9
Survival benefit during zoledronic acid and docetaxel-based chemotherapy in metastatic hormone-refractory prostate cancer patients: an institutional report.唑来膦酸联合多西他赛化疗对转移性激素难治性前列腺癌患者的生存获益：一项机构报告
J BUON. 2011 Oct-Dec;16(4):738-43.
10
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).多西他赛、唑来膦酸和雌莫司汀每周给药用于激素难治性前列腺癌（HRPC）
Invest New Drugs. 2008 Feb;26(1):75-9. doi: 10.1007/s10637-007-9074-3. Epub 2007 Sep 6.